Walgreens today announced that, effective immediately, Walgreens
Infusion Services will serve as a limited network home infusion provider
for BLINCYTO ™ (blinatumomab), a therapy for the treatment of
patients with Philadelphia chromosome-negative (Ph-) relapsed or
refractory B-cell precursor acute lymphoblastic leukemia (ALL).
BLINCYTO™ can now be obtained through and administered by Walgreens
for Walgreens Infusion Services Named a Limited Network Home Infusion Provider for New Continuous Intravenous Infusion Therapy BLINCYTO™ (blinatumomab) Immunotherapy investment picks